Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cogent BiosciencesCOGT +1.41%25 EV-to-OCF is -23.45 as of Aug. 09, 2026. GuruFocus rates COGT with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 1,409 Biotechnology companies, Cogent Biosciences ranks better than 83.11% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cogent Biosciences's Enterprise Value is $6,680.12 Mil.
Cogent Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-284.82 Mil. Therefore, Cogent Biosciences's EV-to-OCF for today is -23.45.
The historical rank and industry rank for Cogent Biosciences's EV-to-OCF or its related term are showing as below:
COGT'
s EV-to-OCF Range Over the Past 10 Years
Min: -34.5 Med: -4.43 Max: 0.55
Current: -23.45
During the past 11 years, the highest EV-to-OCF of Cogent Biosciences was 0.55. The lowest was -34.50. And the median was -4.43.
COGT's EV-to-OCF is ranked better than 83.11% of 1409
companies
in the Biotechnology industry
Industry Median: -3.48
vs COGT: -23.45
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cogent Biosciences's PE Ratio (TTM) for today is calculated as:
Cogent Biosciences's share price for today is $42.39.
Cogent Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.197.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cogent Biosciences EV-to-OCF Related Terms
Cogent Biosciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Cogent Biosciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cogent Biosciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's EV-to-OCF falls into.
Cogent Biosciences's current Enterprise Value is $6,680.12 Mil.
Cogent Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-284.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogent Biosciences (COGT) has a EV-to-OCF of -23.45 as of Aug. 09, 2026. According to the industry distribution chart, Cogent Biosciences ranks #238 out of 1409 companies in the Biotechnology industry, placing it in the top 16.9%.
Is Cogent Biosciences' EV-to-OCF too high?
Cogent Biosciences' current EV-to-OCF is -23.45. Based on the distribution chart, Cogent Biosciences ranks #238 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cogent Biosciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' EV-to-OCF compare to MIRM and ERAS?
According to the Biotechnology industry distribution chart, Cogent Biosciences ranks #238 out of 1409 companies for EV-to-OCF. This places Cogent Biosciences in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Cogent Biosciences's current EV-to-OCF is -23.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current EV-to-OCF of -23.45. The current EV-to-OCF is -23.45. Cogent Biosciences' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current EV-to-OCF is -23.45 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
25GF Score
Get the complete analysis for COGT
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COGT has been successfully added to your 
